Prof. Sarah Ferber Ph.D. serves as Chief Scientific Officer of the Company. Prof. Ferber has served as the Company's Chief Scientific Officer since her appointment on February 2, 2012. Since 2017, Prof. Ferber has been the Principal Investigator of cell therapy for TMU DiaCure. Prof. Ferber studied biochemistry at the Technion under the supervision of Professor Avram Hershko and Professor Aharon Ciechanover, winners of the Nobel Prize in Chemistry in 2004. Most of the research was conducted in Prof. Ferber's Endocrine Research Lab. Prof. Ferber received Teva, Lindner, Rubin and Wolfson awards for this research. Prof. Ferber's research work has been funded over the past 15 years by the JDRF, the Israel Academy of Science foundation (ISF), BIODISC and DCure. Prof. Ferber earned her B.Sc. from Technion-Haifa, a M.Sc. in Biochemistry from Technion-Haifa and a Ph.D. in Medical Sciences from Technion-Haifa. She also holds a Post Doctorate degree in Molecular Biology from Harvard Medical School and a degree in Cell Therapy Sciences from UTSW, Dallas.
As the Chief Scientific Officer of Orgenesis Inc, the total compensation of Sarah Ferber at Orgenesis Inc is $268,783. There are 5 executives at Orgenesis Inc getting paid more, with Vered Caplan having the highest compensation of $1,577,660.
Sarah Ferber is 65, he's been the Chief Scientific Officer of Orgenesis Inc since 2012. There are 1 older and 11 younger executives at Orgenesis Inc. The oldest executive at Orgenesis Inc is Prof. Sarah Ferber Ph.D., 67, who is the Founder & Chief Scientific Officer.
Sarah's mailing address filed with the SEC is C/O ORGENESIS INC., 20271, GOLDENROD LANE, GERMANTOWN, MD, 20876.
Over the last 12 years, insiders at Orgenesis Inc have traded over $4,872,134 worth of Orgenesis Inc stock and bought 375,420 units worth $216,187 . The most active insiders traders include Sca Theodorus, Ii Sa Theodorus a Olivier Belenger. On average, Orgenesis Inc executives and independent directors trade stock every 263 days with the average trade being worth of $1,118,704. The most recent stock trade was executed by Victor Miller on 1 April 2024, trading 25,000 units of ORGS stock currently worth $12,500.
orgenesis inc (orgs) is a medical device company located in 21 sparrow cir, white plains, new york, united states.
Orgenesis Inc executives and other stock owners filed with the SEC include: